New combo therapy tested to shrink tumors before surgery
NCT ID NCT06739252
Summary
This study tested a combination treatment given before surgery for patients with high-risk bile duct cancer that can be removed by an operation. The goal was to see if using chemotherapy delivered directly to the liver, plus two other drugs (atezolizumab and bevacizumab), could better control the cancer and improve outcomes. The trial was terminated early after enrolling only one participant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peing University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.